TB-500: A Fragment Borrowing a Bigger Protein's Record

The short version

TB-500 is a small synthetic peptide — just seven amino acids — with the sequence Ac-LKKTETQ. That sequence is the actin-binding region of a larger natural protein called thymosin beta-4. Actin is part of the internal skeleton cells use to hold their shape and to migrate toward a wound, so the parent protein is closely tied to cell movement, healing, and new blood-vessel growth ^[10].

The single most important thing to understand about TB-500 is a naming gap. In commerce and in anti-doping labs, "TB-500" means the short seven-amino-acid fragment. But most of the published effectiveness research was done with the full-length protein, which is roughly five times larger ^[8]. It is not established that the small fragment reproduces what the whole protein does. TB-500 is not an approved medicine, it is banned in sport, and this page reports figures only as they were studied — never as advice.

What it is

TB-500 is a synthetic, N-terminally acetylated heptapeptide with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln. This LKKTETQ stretch corresponds to residues 17-23 of thymosin beta-4 (Tβ4), a 43-amino-acid protein, and it is the conserved actin-binding region of the beta-thymosin family.

The distinction runs through everything: the fragment sold as "TB-500" weighs about 889 daltons, whereas full-length Tβ4 is about 4,963 daltons. Wherever a study below used the full protein rather than the 7-mer, this page flags it — because that is exactly where TB-500 marketing tends to borrow a larger molecule's data ^[8].

How it works

Full-length thymosin beta-4 is the body's major intracellular G-actin sequestering peptide. G-actin is the free, single-unit form of actin; sequestering means Tβ4 grabs and holds those units so they are not assembled into filaments until the cell needs them. A 2-angstrom X-ray crystal structure of a gelsolin-Tβ4 hybrid bound to actin established that Tβ4 forms a 1:1 complex with G-actin and caps both ends of the monomer, preventing polymerization — the structural basis for its actin-buffering role ^[12].

Why does that matter for repair? By regulating the actin skeleton, Tβ4 (and the LKKTETQ motif it contains) is associated with faster cell migration, new blood-vessel growth, anti-inflammatory and anti-apoptotic signaling, reduced scar-forming myofibroblasts, and recruitment of progenitor cells — a mechanism reviewed across wound, corneal, heart and CNS models ^[10]. Whether the isolated seven-amino-acid fragment reproduces all of that at the doses used in peptide research has not been shown in controlled human trials ^[10].

What the research shows

Structural and mechanistic basis. The crystallography work pinned down the 1:1 actin-capping mechanism ^[12], and a multi-model review consolidated Tβ4's actin-binding, pro-migratory, anti-scarring, anti-inflammatory and angiogenic activities as the rationale for clinical development in dermal wounds, corneal injury, and heart and CNS repair ^[10].

Human safety (full-length protein). In a randomized, placebo-controlled Phase 1 study, synthetic thymosin beta-4 was given intravenously to 40 healthy volunteers — a single dose then daily for 14 days at 42, 140, 420 or 1260 mg. It was well tolerated, with only infrequent mild-to-moderate adverse events, no dose-limiting toxicities and no serious adverse events, and dose-proportional pharmacokinetics ^[11]. Note carefully: this used full-length Tβ4, not the TB-500 fragment.

Animal dose-response. In male Wistar rats with an embolic stroke model, intraperitoneal thymosin beta-4 (2, 12 or 18 mg/kg starting 24 hours after stroke, then every three days) improved neurological function at 2 and 12 mg/kg, but 18 mg/kg gave no significant benefit — a non-monotonic result where more was not better ^[9].

Field-level review. A 2026 Sports Medicine narrative review listing TB-500/thymosin beta-4 and BPC-157 among unapproved peptides concluded that many such peptides show favorable tissue-repair outcomes in animal models, but that rigorous human safety data are scarce, the potential for serious harm exists, and these compounds operate largely outside regulatory oversight ^[8].

Reported effects, cautions & safety

The cautions for TB-500 are unusually concrete, and several are specific to this compound:

• Identity confusion. Because "TB-500" is the fragment but most efficacy data come from full-length Tβ4, efficacy claims for the fragment in humans are unproven ^[8]. No completed controlled clinical trials of the TB-500 fragment exist for any indication.
• Tumor/angiogenesis signal. Thymosin beta-4 is overexpressed in several cancers (for example pancreatic and colorectal) and is implicated in metastasis and tumor angiogenesis; the same pro-migratory, pro-angiogenic properties that support repair could, in theory, support tumor progression ^[10].
• Mixed and negative preclinical results. In dystrophin-deficient mice, chronic Tβ4 increased regenerating fibers but did not improve muscle strength, cardiac function or fibrosis; and systemic Tβ4 failed to reduce myocardial ischemia-reperfusion injury in a pig study ^[8][10].
• Non-monotonic dosing. The rat stroke study's finding that 18 mg/kg helped less than 12 mg/kg undermines community "loading" rationales — higher is not necessarily better ^[9].
• Regulatory. TB-500 is prohibited in sport by WADA and is a prescription medicine in some jurisdictions; it has appeared as a designer doping agent in racehorses, prompting dedicated detection assays ^[8].

No community-anecdote signals are compiled in this desk's source material for TB-500, so none are presented; the points above are drawn from the cited literature.

Where it fits in recovery research

TB-500 occupies a particular niche on this desk: a compound whose mechanism — actin regulation driving cell migration — is well described at the protein level, but whose evidence as the actual marketed fragment is the thinnest of the three ^[8]. Where BPC-157 leads with angiogenesis and GHK-Cu leads with matrix-building and human topical data, TB-500's story is really thymosin beta-4's story, borrowed. That makes it the clearest case study in why this field rewards careful reading. See how it lines up on the comparison page.